Publications by authors named "Rujuta Joshi"

Claim this Profile
E
Exposure-Response Relationships in Patients with Non-Small-Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3-DXd).
Li Li, Mark Lee, Rujuta Joshi, Yuan Xu, Ramon Garcia

Clin Pharmacol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors.
Yuan Xu, Mark Lee, Rujuta Joshi, Xiaoning Wang, Hillary Husband

Clin Pharmacokinet· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of Judd-Ofelt Parameters for LiGdY:Eu O Nanophosphor Synthesis by Combustion Method With Glycine as Fuel for Near UV Light Emitting Diode.
Milind A Patwardhan, Ritesh L Kohale, Ritesh K Jumale, Sarika A Khapre, Rujuta K Joshi

Luminescence· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial.
Sven Stodtmann, Doerthe Eckert, Rujuta Joshi, Silpa Nuthalapati, Christine K Ratajczak

J Clin Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
Sven Stodtmann, Silpa Nuthalapati, Doerthe Eckert, Sreeneeranj Kasichayanula, Rujuta Joshi

J Clin Pharmacol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Gautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, David A Rizzieri, Thomas Prebet, Rujuta H Joshi

Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deficiency of N-acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver.
Pengcheng Wang, Amina I Shehu, Jie Lu, Rujuta H Joshi, Raman Venkataramanan

Biochem Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis.
Hongfei Zhang, M Hong Nguyen, Cornelius J Clancy, Rujuta Joshi, Wenchen Zhao

Antimicrob Agents Chemother· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
Randy M Windreich, Rakesh K Goyal, Rujuta Joshi, Tanya S Kenkre, Denise Howrie

Biol Blood Marrow Transplant· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transition from brand to generic tacrolimus is associated with a decrease in trough blood concentration in pediatric heart transplant recipients.
Son Q Duong, Ashwin K Lal, Rujuta Joshi, Brian Feingold, Raman Venkataramanan

Pediatr Transplant· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis